Matthew L. Kaplan's Insider Trades & SAST Disclosures

Matthew L. Kaplan's most recent trade in Nuvectis Pharma Inc was a trade of 30,000 Common Stock done . Disclosure was reported to the exchange on June 13, 2024.

Stock Client Name Client Category Action Reported to Exchange Quantity Post Transaction Holding Traded % Avg. Price Value Security Type
Nuvectis Pharma Inc
Matthew L. Kaplan Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Jun 2024 30,000 83,760 - 0 Common Stock
Nuvectis Pharma Inc
Matthew L. Kaplan Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Jun 2023 18,000 53,760 - 0 Common Stock
Nuvectis Pharma Inc
Matthew L. Kaplan Director Purchase of securities on an exchange or from another person at price $ 17.47 per share. 12 May 2022 1,823 35,760 - 17.5 31,848 Common Stock
Nuvectis Pharma Inc
Matthew L. Kaplan Director Purchase of securities on an exchange or from another person at price $ 15.96 per share. 12 May 2022 1,177 33,937 - 16.0 18,785 Common Stock
Nuvectis Pharma Inc
Matthew L. Kaplan Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Apr 2022 15,000 15,000 - - Stock Options (right to buy)
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc  
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges
View All The Insider Trades